Prime Highlights:
- Chugai is shifting from internal R&D to global collaborations, partnering with companies like Rani Therapeutics and Araris Biotech to advance drug delivery and antibody-drug conjugates.
- The company continues to leverage Japanese academic expertise, including a collaboration with Nobel laureate Shimon Sakaguchi on cancer therapies.
Key Facts:
- In 2023, Chugai launched a $200 million Venture Fund in Boston to support innovation in the U.S. and Western Europe.
- Chugai opened a large research center in Yokohama, Japan, hiring over 1,000 scientists to strengthen the local biotech ecosystem.
Background:
Chugai Pharmaceutical is working to raise its profile on the global stage while continuing to push the boundaries of drug discovery. Speaking at the J.P. Morgan Annual Healthcare Conference in San Francisco, company leaders emphasized the importance of building connections within the broader biopharma ecosystem.
“Chugai’s name is not widely recognized internationally, even though some of our products are well-known within the industry,” said Osamu Okuda, Ph.D., president and CEO of the Roche subsidiary. The company hopes to change that perception while exploring opportunities for collaboration and scientific advancement.
Chugai has a strong track record in drug innovation. The company developed Roche’s blockbuster hemophilia treatment, Hemlibra (emicizumab), and the small molecule GLP-1 drug orforglipron, which was licensed to Eli Lilly in 2018 and is awaiting FDA approval this spring. Chugai also pioneered “recycling antibodies,” an early approach to protein degradation, with its first approved therapy, Enspryng (satralizumab), receiving FDA approval in 2020.
Looking ahead, Chugai is shifting its focus from only internal research to working with external partners. The company recently partnered with California-based Rani Therapeutics to explore oral delivery of antibody therapies using Rani’s RaniPill technology. It also teamed up with Araris Biotech to develop antibody-drug conjugates, in a deal that could reach $780 million if milestones are met.
The company is also investing globally. In 2023, it launched a $200 million Chugai Venture Fund in Boston to support innovation in the U.S. and Western Europe. Its most recent investment supported Bay Area biotech Dualitas Therapeutics, which is developing next-generation bispecific antibodies.
Japan is still central to Chugai’s plans. The company opened a big research center in Yokohama and hired over 1,000 scientists to support the country’s growing biotech industry.
Chugai is emerging as a leader in pharmaceuticals.
Read Also: AbbVie Pledges $100 Billion to U.S. R&D and Manufacturing in Deal with Trump Administration
